Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Alto Neuroscience, Inc. regarding a class action lawsuit due to alleged misleading statements about the company's product pipeline and financial prospects [1][4]. Group 1: Class Action Details - The class action lawsuit is on behalf of all persons and entities that purchased Alto common stock during the class period from February 2, 2024, to October 22, 2024 [3]. - Shareholders are encouraged to contact the Gross Law Firm for possible lead plaintiff appointment, although it is not required to partake in any recovery [1][5]. Group 2: Allegations - The complaint alleges that during the class period, the defendants made materially false and misleading statements regarding the effectiveness of the product ALTO-100 in treating major depressive disorder [4]. - It is claimed that the clinical, regulatory, and commercial prospects of ALTO-100 were overstated, leading to an inflated perception of Alto's business and financial prospects [4]. Group 3: Next Steps for Shareholders - Shareholders must register by September 19, 2025, to participate in the class action and will be enrolled in a portfolio monitoring software for updates [5]. - There is no cost or obligation for shareholders to participate in the case [5]. Group 4: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered from deceit and fraud [6]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [6].

Core Points - A class action lawsuit has been filed against Alto Neuroscience, Inc. for violations of federal securities laws [1][2] - The lawsuit claims that Alto made false and misleading statements regarding the effectiveness of its treatment ALTO-100 for major depressive disorder [2] - The class period for the lawsuit is from February 2, 2024, the date of Alto's IPO, to October 22, 2024 [2] Company Details - Shareholders who purchased shares during the class period are encouraged to contact DJS Law Group for potential lead plaintiff appointments [1][3] - The deadline for shareholders to register for participation in the lawsuit is September 19, 2025 [2] - DJS Law Group specializes in securities class actions and corporate governance litigation, representing large hedge funds and alternative asset managers [4]

Core Viewpoint - The Gross Law Firm has announced a class action lawsuit on behalf of shareholders of Alto Neuroscience, Inc. (NYSE: ANRO) who purchased shares during a specified class period, alleging that the company made materially false and misleading statements regarding its product pipeline and business prospects [1][2]. Group 1: Class Action Details - The class period for the lawsuit includes all persons and entities that purchased Alto common stock from February 2, 2024, to October 22, 2024 [1]. - Shareholders are encouraged to register for the class action by September 19, 2025, to potentially be appointed as lead plaintiff [3]. Group 2: Allegations Against Alto Neuroscience - The complaint alleges that the product pipeline, specifically ALTO-100, was less effective in treating major depressive disorder than previously claimed, leading to overstated clinical and commercial prospects [2]. - As a result of these misleading statements, Alto's overall business and financial outlook were also overstated [2]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect the rights of investors who have suffered losses due to deceit and illegal business practices, emphasizing the importance of responsible corporate behavior [4].

Core Viewpoint - Alto Neuroscience, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding the effectiveness of its drug ALTO-100 during its IPO and subsequent clinical trials [3][4][5]. Company Overview - Alto Neuroscience operates as a clinical-stage biopharmaceutical company [3]. - The company conducted its IPO on February 2, 2024, issuing over 8 million shares at $16.00 per share, raising over $119 million [3]. Product Pipeline - The product pipeline includes ALTO-100, which was in a Phase 2b clinical trial for treating major depressive disorder (MDD) at the time of the IPO [3]. Allegations of Misleading Information - The lawsuit claims that the company made false or misleading statements about ALTO-100's effectiveness in treating MDD, overstating its clinical, regulatory, and commercial prospects [4]. - It is alleged that these misrepresentations led to an overestimation of Alto Neuroscience's overall business and financial prospects [4]. Impact of Clinical Trial Results - On October 22, 2024, the company announced that ALTO-100 did not meet its primary endpoint in the Phase 2b trial, resulting in a nearly 70% drop in stock price [5]. - Following this announcement, Alto Neuroscience's stock continued to trade below the IPO price of $16.00 per share [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Alto Neuroscience, Inc. during the IPO and the subsequent class period about the upcoming lead plaintiff deadline for a class action lawsuit [1][5]. Group 1: Class Action Details - Investors who purchased Alto securities may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by September 19, 2025 [3]. - The lawsuit alleges that during the class period, Alto made materially false and misleading statements regarding its business and the effectiveness of its product ALTO-100 for treating major depressive disorder [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [4].

Core Viewpoint - A class action has been filed against Alto Neuroscience, Inc. for allegedly misleading investors regarding the effectiveness of its drug candidate ALTO-100 during its IPO and subsequent period [1][2]. Group 1: Company Overview - Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the U.S. with a product pipeline that includes ALTO-100, which was in a Phase 2b clinical trial for treating major depressive disorder (MDD) at the time of its IPO [1]. Group 2: Allegations and Misconduct - The complaint alleges that the Offering Documents for the IPO were negligently prepared and that the company failed to disclose that ALTO-100 was less effective in treating MDD than represented, leading to overstated clinical, regulatory, and commercial prospects [2]. - The company's business and financial prospects were also claimed to be overstated as a result of these misrepresentations [2]. Group 3: Impact of Trial Results - On October 22, 2024, Alto announced that ALTO-100 did not meet its primary endpoint in the Phase 2b trial, resulting in a significant stock price drop of $10.17 per share, or 69.99%, closing at $4.36 per share on October 23, 2024 [3]. Group 4: Class Action Participation - Shareholders interested in participating in the class action against Alto have until September 19, 2025, to seek lead plaintiff status, which allows them to represent other class members in the litigation [4].

ATLANTA, Sept. 02, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Alto Neuroscience, Inc. (“Alto” or the “Company”) (NYSE: ANRO). The lawsuit alleges that throughout the Class Period, and in the Company’s Offering Documents, Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information concerning Alto’s business, operations, and prospects, including allegations that: (i) ALTO-100 was less effective in treating MDD tha ...

NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Alto Neuroscience, Inc. (“Alto” or the “Company”) (NYSE: ANRO) and certain officers.   The class action, filed in the United States District Court for the Northern District of California, and docketed under 25-cv-06105, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Alto common stock pursuant and/or traceable t ...

NEW YORK, Sept. 2, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. ("Alto Neuroscience, Inc." or the "Company") (NYSE: ANRO) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Alto Neuroscience, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class consisting of all persons and entities that purchased or otherwise acquired: (a) Alto common stock pursuant and/or ...

NEW YORK, Sept. 1, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Alto Neuroscience, Inc. (NYSE: ANRO): (i) pursuant and/or traceable to Alto's initial public offering conducted on or about February 2, 2024 (the "IPO"); and/or (ii) securities between February 2, 2024 and October 22, 2024, both dates inclusive (the "Class Period"), of the important September 19, 2025 lead plaintiff deadline.So What: If you purchased Alto securities you may be ent ...